BOUL: Sales declined, but margins and EBIT improved amid restructuring and strong OEM growth

About this update from Boule Diagnostics Ab

Q3 saw a 6.6% sales decline, but gross margin and EBIT improved due to cost savings and a favorable mix. Major one-time costs included a SEK 265 million impairment and SEK 27 million write-down, while OEM growth and restructuring initiatives support a positive outlook for 2025. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab